News for Cassava Sciences, Inc. (SAVA)

Cassava Sciences, trading under the ticker SAVA, has welcomed Angelique Bordey, PhD, to their team as Senior Vice President of Neuroscience. Her role within the

Cassava Sciences (SAVA) appoints Dr. Angélique Bordey as Senior Vice President of Neuroscience. Dr. Bordey's research has led to a new patent for simuf

**media[611530]**

**media[600877]**

Summary: Cassava Sciences has halted its Alzheimer's drug development after failing Phase III trials. The company's stock has suffered a significant decl

Cassava Sciences (SAVA) embroiled in legal battles and research controversy. Analysts project a 62.60% potential upside on SAVA's current stock price.

The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzhe

Cassava Sciences (SAVA) stock falls as the company halts Alzheimer's drug program after trial failures. Read more here.

Cassava Sciences explores simufilam's potential for seizures in tuberous sclerosis. Results for Alzheimer's trials expected Q1/Q2 2025. Learn more on SAVA stock here.

Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreem

**media[555352]**

**media[552075]**

PR NewswireNEW YORK, Feb. 10, 2025 NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Scienc

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassa

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. ( SAVA). Shareholders wh

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, In